Clinical Trials Browser

Melanoma × Radiotherapy × 1 year × Clear all

Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT00508443 2026-01-15

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Phase 1/2 Active not recruiting

150 enrolled

BreastDermatologicGastrointestinalLymphoidSarcomaThoracic

Urogenital Diseases, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms, Sarcoma, Spinal Diseases, Spinal Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

14 enrolled

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT05893654 2025-09-15

MELCOM

Phase 1/2 Enrolling by invitation

10 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Phase EARLY_PHASE1 Completed

18 enrolled

Dermatologic

Melanoma

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1 Completed

41 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1 Completed

13 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Active not recruiting

8 enrolled

Dermatologic

Melanoma

Clinical Trials

MelPORT

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

MELCOM

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma